The process to sell Nestle’s skin health division is off to a good start, with strong interest in the business following an overhaul, the chief executive said on Thursday.
“We’ve seen very, very strong interest in this process, and literally people lining up around the block to be part of this process,” Chief Executive Mark Schneider told analysts in a conference call.
First round bids for the unit, which is expected to fetch around 7 billion Swiss francs ($7 billion), are due on 6 March, two sources familiar with the matter said on Thursday.
Nestle declined to comment on the deadline.
Another source said the unit, which sells Cetaphil and Proactiv skin care products, Restylane wrinkle fillers and prescription dermatology medicines, is particularly attractive to private equity firms, since there are not many assets of this size available.
Reuters reported last month that private equity firms Cinven and Advent had teamed up to submit a joint offer, while several other firms were also expected to bid.
CEO Schneider said the business was operating from a position of strength following “significant, impressive progress” in performance over the past 2.5 years.
He said a similar turnaround had taken place at the Herta charcuterie business, which is also up for sale.
That business, which is particularly big in France but present in other parts of Europe, had sales of about 680 million Swiss francs last year, Schneider said.
Nestle shares were up more than 2 percent at 1445 GMT on Thursday after the company reported higher 2018 sales and forecast further growth this year, as Schneider’s overhaul takes hold. ($1 = 1.0057 Swiss francs)
By Martinne Geller and Arno Schuetze
The company expects to eliminate 1.2 billion tons carbon dioxide equivalent of methane emissions by the end of the decade. The company says that it already reduced its methane emissions by around 14% between 2018 and 2020.
The “first-of-its-kind” pilot project will develop and demonstrate an affordable modular bioprocessing system to produce biodegradable bioplastics from food waste diverted from landfills. The three-year grant will test the scalability and feasibility of the conversion on a national and global scale.
Arkeon is allying with specialty mineral giant ICL to support the scaling of its fermentation bioprocess that converts CO2 into the 20 proteinogenic essential amino acids needed in human nutrition. The process, hailed as carbon negative, is based on the use of archaea, a group of microorganisms that naturally feeds off the greenhouse gas.